The scoop: Marathon’s R&D pro­gram for Duchenne MD drug like­ly came in at a bar­gain base­ment price

On Fri­day, as news spread about the FDA’s ap­proval of Marathon Phar­ma­ceu­ti­cals’ ap­pli­ca­tion for Em­flaza (de­flaza­cort) as an or­phan drug for Duchenne mus­cu­lar dy­s­tro­phy, CEO Jeff Aronin went on the of­fen­sive over his plans to sell the drug at an $89,000 list price, which im­me­di­ate­ly drew scruti­ny from some long­time ob­servers of the in­dus­try.

Aronin pulled what has be­come a stan­dard play out of the guide book for phar­ma com­pa­nies fac­ing price goug­ing charges. He told re­porters at sev­er­al pub­li­ca­tions, in­clud­ing the Chica­go Tri­bune and the Wall Street Jour­nal, that it would take years for Marathon to be­come prof­itable, con­sid­er­ing all the R&D costs that had been sunk in­to de­flaza­cort. And — like Tur­ing founder Mar­tin Shkre­li, caught on the horns of a con­tro­ver­sy over Dara­prim pric­ing — he vowed that pa­tients would be pro­tect­ed, with pay­ers cov­er­ing the cost.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER